Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
RedHill Biopharma Announces Allowance of a Patent in Japan Supporting RHB-104 for Multiple Sclerosis
RedHill has received from the Japan Patent Office a Notice of Allowance for a new patent covering RHB-104 for multiple sclerosis (MS), expected to be valid until 2032, once granted RedHill’s...
-
TEL-AVIV, Israel, Oct. 13, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on development and...
-
TEL-AVIV, Israel, Oct. 06, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on development and...
-
An option for early stop for success for overwhelming efficacy has been introduced into the ongoing first Phase III study with RHB-104 for Crohn’s disease (the “MAP US” study) and analysis is...
-
The Phase II clinical study is intended to evaluate the efficacy and safety of YELIVA™ (ABC294640) in patients with advanced hepatocellular carcinoma (HCC), the most common primary malignant cancer...
-
TEL-AVIV, Israel, Sept. 27, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on development and...
-
RIZAPORT® (5 mg and 10 mg) was granted marketing approval in Germany under the European Decentralized Procedure (DCP)This binding term sheet for the license of RIZAPORT® in South Korea follows a...
-
TEL-AVIV, Israel, Sept. 12, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on development and...
-
The Phase Ib/II clinical study is intended to evaluate the safety and efficacy of YELIVA™ (ABC294640) in patients with refractory or relapsed multiple myeloma and is supported by a $2 million grant...
-
TEL-AVIV, Israel, Sept. 01, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on development and...